Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: DAN LITTLE who wrote (328)	6/8/1998 5:18:00 PM
From: OLD JAKE JUSTUS	Respond to of 4891

Thanks for the hard work, Dan! I am grateful to you for your exerted effort in searching for who will be publishing the Barbados Paper. I have heard that it is an prestigious foreign journal, of world renown. But, I don't know where or when it will be published, nor does any of my friends and associates that I have asked this question to. It could be published anywhere and at anytime. I guess it could never be published. It will be published or it will not be published. We must wait and see if it is. I am guessing that our good friend, the paper man, will be disappointed, that you did not find out anything. But, thanks for the try! "An idea is something that usually comes like firemen....too late!", Jewish Saying, as reported in "The Great Business Quotations", compiled by Rolf B. White, 1986.

To: DAN LITTLE who wrote (328)	6/8/1998 5:54:00 PM
From: BARRY ALLEN	Read Replies (2) \| Respond to of 4891

Hey, hey, hey.......the word is getting out! Now, if only the NY Times, USA Today, etc. would get a hold of this remarkable event!! ************************************************* Dateline: Sunday-June-07-1998 ------ Barbados----News-General Aid For AIDS Victims by Terry Ally AT LEAST 12 AIDS patients in Barbados remain alive and well two years after being put on a trial drug that fights the virus. The patients, part of a study of the drug Reticulose at the Queen Elizabeth Hospital, have recovered significantly and reportedly doing well. Most of them using the low-cost drug are well enough to continue working while one is so well that he emigrated a few months ago to start a new life in another country, said the three trial doctors. Of the original 43 patients tested, 21 opted to continue the treatment. Some, who were in the advanced stage of the disease died, and 12 remained on the treatment. But Professor Henry Fraser, Dr. Timothy Roach, and Dr. Paul Levett said that they were uncertain about when the US-manufactured drug would be available commercially in Barbados. "The FDA has not expressed much interest in this drug," said Fraser. "This drug is the poor relation, the little radical on the outskirts in which people are not particularly interested because it is so cheap and because it has been around for a long time." Fraser, a member of the board of the Barbados Drug Service, said drugs were not sold commercially here before they were registered and approved for sale in the country of manufacture. "In Barbados, however, we do not have a registration process so there is a possibility of this drug being made available earlier and this is something that the drug service would have to work its way through when it is offered or it may be that the manufacturer may have to set up a plant outside of the USA." However, Fraser said that much more information was needed about the drug which was first manufactured 40 years ago to treat a wide range of viral infections including influenza, chicken pox, and childhood measles and was widely available. It has proven as effective as AZT, when used as a single therapy, but nothing is known about its effectiveness in the triple therapy "cocktail" of drugs or what doses should be used. AZT attacks the HIV virus directly but Reticulose works indirectly by stimulating the immune system to create more CD8 cells which hunt down and kill the virus, multiplying the CD4 cells which are the ones the virus attacks. At the same time the drug reduces the "viral load" - the amount of the virus in the blood. One complaint by patients, said Roach, was that Reticulose was given by injection once or twice daily but Fraser said when it made the difference between life and death, people would use it. nationnews.com (hit on "Local" section and scroll down)